A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Clinical trial NCT01614756 · COMPLETED

Trial details

NCT number: NCT01614756
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Healthy Subjects and Atopic Dermatitis Subjects

Start date: 2012-07-01
Primary completion: 2015-04-01
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.